

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 2, 2021

STRATA  
SKIN SCIENCES

STRATA SKIN SCIENCES, INC.  
(Exact Name of Registrant Specified in Charter)

Delaware  
(State or Other  
Jurisdiction of  
Incorporation)

000-51481  
(Commission File  
Number)

13-3986004  
(I.R.S. Employer  
Identification No.)

5 Walnut Grove Drive, Suite 140, Horsham, 19044  
Pennsylvania  
(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: 215-619-3200

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.001 par value per share	SSKN	The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 7.01. Regulation FD Disclosure.**

On August 2, 2021, Strata Skin Sciences (the “Company”) announced the appointment of Brent Cowgill as Vice President of Marketing. Mr. Cowgill has over 20 years of healthcare sales and marketing experience. Prior to joining the Company he managed Vantage Marketing, a healthcare consulting firm which he founded 9 years ago, that focused on commercializing prescription treatments in the U.S. market. Brent has held various commercial positions at both Fortune 500 and emerging healthcare companies. His roles and responsibilities, while varied, stayed focused on supporting the strategic and commercial efforts at companies such as Graceway Pharmaceuticals, Bioglan Pharmaceuticals, and Bristol Myers Squibb. Mr. Cowgill holds a B.S. degree in Marketing from Bowling Green State University.

The information set forth under this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits:

99.1 [Press release, dated August 2, 2021.](#)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**STRATA SKIN SCIENCES, INC.**

Date: August 3, 2021

By: /s/ Matthew C. Hill  
Matthew C. Hill  
Chief Financial Officer

**Strata Skin Sciences Announces Appointment of New VP of Marketing**

**Horsham, Pa., August 2, 2021** — STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (“STRATA” or the “Company”), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced the appointment of Brent Cowgill as Vice President of Marketing.

“We are delighted to welcome Mr. Cowgill to the STRATA team,” said Robert J. Moccia, Chief Executive Officer of STRATA. “His extensive background in healthcare sales and marketing will prove to be invaluable in the execution of our strategic marketing efforts to both customers and dermatologists. One of our highest priorities at STRATA is driving superior commercial execution and we believe that Brent is the ideal leader to help us achieve and maintain this goal.”

Mr. Cowgill has over 20 years of healthcare sales and marketing experience. Prior to joining STRATA he managed Vantage Marketing, a healthcare consulting firm which he founded 9 years ago, that focused on commercializing prescription treatments in the U.S. market. Brent has held various commercial positions at both Fortune 500 and emerging healthcare companies. His roles and responsibilities, while varied, stayed focused on supporting the strategic and commercial efforts at companies such as Graceway Pharmaceuticals, Bioglan Pharmaceuticals, and Bristol Myers Squibb. Mr. Cowgill holds a B.S. degree in Marketing from Bowling Green State University.

“I am very excited to join the STRATA team,” said Mr. Cowgill. “I look forward to helping STRATA expand its presence within the dermatology market while building upon XTRAC's commercial success as the market’s leading excimer laser technology used to treat several chronic skin conditions that afflict millions of people worldwide.”

**About STRATA Skin Sciences, Inc.**

STRATA Skin Sciences is a medical technology company in dermatology dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions. Its products include the XTRAC® excimer laser and VTRAC® lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions.

The Company’s proprietary XTRAC excimer laser delivers a highly targeted therapeutic beam of UVB light to treat psoriasis, vitiligo, eczema, atopic dermatitis and leukoderma, diseases which impact over 31 million patients in the United States alone. The technology is covered by multiple patents.

STRATA’s unique business model leverages targeted Direct to Consumer (DTC) advertising to generate awareness and utilizes its in-house call center and insurance advocacy teams to increase volume for the Company’s partner dermatology clinics.

**Investor Contact**

Leigh Salvo  
(415) 937-5404  
ir@strataskin.com

---

---